Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn
About

Company News Summary

CSL Provides an Update on Agreement with uniQure

06 May 2021  |  14:17:00  |  Associate analysts  |  Increase  |  Decrease  |  

Original announcement: Update on CSL Agreement with uniQure

CSL provided an update stating that the company announced the closing of the company's global commercialisation and license agreement with uniQure for etranacogene dezaparvovec (AMT-061), a novel gene therapy for the treatment of haemophilia B. The company stated that the global licensing agreement was announced on 24 June 2020 and the closing follows the completion of antitrust reviews of the transaction in the US, the UK and Australia. The company also reported that under the terms of the agreement, uniQure will receive an cash payment of US$450 million by 13 May, 2021.

Please click here for full details

See more ASX300 News Announcements